Skip to main content
. 2020 Aug 2;10(21):9808–9829. doi: 10.7150/thno.43631

Figure 8.

Figure 8

Biodistribution and in vivo antitumor therapeutics of CaO2@HMSNs-PAA. (A) Biodistribution of CaO2@HMSNs-PAA (CHP) in the subcutaneous PC-3 xenografted tumor-bearing BALB/c nude mice at 3 h, 6 h, 12 h and 24 h after intravenous injection (n = 3). (B-C) Body weights (B) and relative tumor volumes (C) of the PC-3 tumor-bearing nude mice recorded after intravenous administration of phosphate-buffered saline (PBS), HMSNs (H), HMSNs-PAA (HP), CaO2 (C), CaO2@HMSNs (CH) and CaO2@HMSNs-PAA (CHP) (n = 5) (*, p < 0.05, vs. the PBS group; **, p < 0.01, vs. the PBS group; ▲▲, p < 0.01, comparison between the CH group and the CHP group). (D) Kaplan-Meier survival analysis of the PC-3 tumor-bearing BALB/c nude mice, with the definition of survival as the tumor volume (V) failed to exceed two times of the initial volume (V0) (**, p < 0.01, vs. the PBS group). (E) Tumor weights and tumor sizes on day 14 after intravenous administration of PBS, H, HP, C, CH and CHP (n = 5) (*, p < 0.05, vs. the PBS group; **, p < 0.01, vs. the PBS group; ▲, p < 0.05, comparison between the CH group and the CHP group). Scale bar, 1 cm. Data are presented as the mean ± SD.